Methyclothiazide

Methyclothiazide is an orally active antihypertensive agent and a diuretic agent. Methyclothiazide leads to a reduction of the vascular response to the action of endogenous vasoconstricting stimuli, such as Norepinephrine (HY-13715) . Methyclothiazide is against voltage-dependent Ca-channel (VDCC) activity in vitro[1][2][3].

Product Specifications

CAS Number

[135-07-9]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Carbonic Anhydrase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/methyclothiazide.html

Purity

99.76

Solubility

DMSO : 72 mg/mL (ultrasonic; warming) |H2O : < 0.1 mg/mL

Smiles

O=S(C1=C(Cl)C=C(C2=C1)NC(CCl)N(C)S2(=O)=O)(N)=O

Molecular Formula

C9H11Cl2N3O4S2

Molecular Weight

360.24

Precautions

H315, H319, H335

References & Citations

[1]Colas, B., et al., Mechanisms of methyclothiazide-induced inhibition of contractile responses in rat aorta. Eur J Pharmacol, 2000. 408 (1) : p. 63-7.|[2]Colas, B., et al., Direct vascular actions of methyclothiazide and indapamide in aorta of spontaneously hypertensive rats. Fundam Clin Pharmacol, 2000. 14 (4) : p. 363-8.|[3]Sasaki, S. and R.D. Bunag, Methyclothiazide attenuates salt-induced hypertension without affecting sympathetic responsiveness in Dahl rats. J Cardiovasc Pharmacol, 1983. 5 (3) : p. 378-83.